CFO Scott Kathleen D. sold 50,000 shares (87.1% of holdings) at $14.10, retaining 7,424 shares in loss-making biotech SPRY.
Scott Kathleen D., Chief Financial Officer of ARS Pharmaceuticals, executed a substantial open-market sale of 50,000 shares at $14.10 on 2025-05-20, reducing her holdings from 57,424 to 7,424 shares—a 87.1% reduction in position size. The transaction occurs at $14.10 while the stock currently trades at $14.52, a 2.9% premium to the sale price. The company reported a net loss of $33,940,000 in its latest quarter against revenue of $7,973,000, and the P/E of 181.50 reflects the challenge of valuing a pre-profitability or loss-making firm. The 90-day price appreciation of 29.2% and annual revenue growth of 297063.3% suggest significant positive momentum, yet the CFO's near-complete position liquidation represents a substantial reduction in her stake despite this upward trend. The transaction warrants monitoring for context around capital allocation decisions, vesting schedules, or personal financial planning by the company's chief financial officer.